Abstract 3752
Background
The expanding armamentarium of wearable devices offers new opportunities to supplement physician-assessed performance status (PS) with continuously acquired real-life patient data. It is relevant to identify and characterize the level of association between wearable device physical activity (PA) metrics and PS in cancer patients as a first step into evaluating their potential combined utility in evaluating treatment outcomes and clinical decisions. Therefore, we conducted a systematic review to examine the association between wearable device PA metrics and PS in cancer patients.
Methods
We searched PubMed and EMBASE for studies that were conducted among adults with cancer, quantitatively assessed a relation between wearable device PA metrics and PS, and had a full text available in English. We extracted information on study design and population, wearable device type and PA metrics, outcome definitions, and results. Included studies were subjected to methodological quality assessment.
Results
Nine studies with a total of 574 patients were included in this review. Eight studies had a prospective observational study design and all studies reported on a different combination of wearable device PA metrics including: steps per day (n = 5), sedentary behavior (n = 5), and PA volume/intensity (n = 4). Much heterogeneity was observed regarding study population, wearable devices used, and reporting of results. None of the studies could be defined to be of ‘high methodological quality’ (≥ 70%): mean methodological quality was 47% and ranged from 40-60%. We found moderate evidence for a positive association between steps per day and PS, and for a negative association between sedentary behavior and PS.
Conclusions
Much heterogeneity was identified between studies with regards to study population, reported PA metrics, and used devices. Nevertheless, results of this study indicate that higher daily step count is associated with better PS in cancer patients. Whereas sedentary behavior is associated with worse PS. The next step into determining their potential combined utility in evaluating treatment outcomes and clinical decisions is to investigate the association between wearable device PA metrics and cancer outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.W. Wilmink: Advisory / Consultancy: Shire; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Halozyme; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Merck. H.W.M. van Laarhoven: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Philips. M. van Oijen: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract